Small Cell Lung Cancer News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Reimbursement Landscape for Molecular Testing in Non-Small Cell Lung Cancer - AJMC.com Managed Markets Network



Reimbursement Landscape for Molecular Testing in Non-Small Cell Lung Cancer 
AJMC.com Managed Markets Network
... Non?small-cell lung cancer (NSCLC) is the most common form of lung cancer, representing approximately 85% of all cases.3 NSCLC is characterized by a number of genomic alterations (mutations, rearrangements, and amplifications), and these ...

 


FDA expands approval of Imfinzi to reduce the risk of non-small cell lung cancer progressing - FDA.gov



Reuters
 
FDA expands approval of Imfinzi to reduce the risk of non-small cell lung cancer progressing 
FDA.gov
?This is the first treatment approved for stage III unresectable non-small cell lung cancer to reduce the risk of the cancer progressing, when the cancer has not worsened after chemoradiation,? said Richard Pazdur, M.D., director of the FDA's Oncology ...
US FDA APPROVES IMFINZIŽ (DURVALUMAB) FOR UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER PR Newswire (press release)
FDA Approves Imfinzi for Locally Advanced Non-Small Cell Lung Cancer Curetoday.com
AstraZeneca's immunotherapy drug wins key lung cancer approval Reuters
OncLive  -Medscape  -Endpoints News 
all 13 news articles » 


ALK Inhibitors Continue to Reshape Treatment in NSCLC - OncLive



OncLive
 
ALK Inhibitors Continue to Reshape Treatment in NSCLC 
OncLive
It is an exciting time in the treatment landscape of ALK-positive non?small cell lung cancer (NSCLC), as there have been a number of regulatory decisions and clinical trial findings with regard to ALK-specific tyrosine kinase inhibitors (TKIs ...

and more » 


FDA expands approval of Imfinzi in non-small cell lung cancer - EPM Magazine



EPM Magazine
 
FDA expands approval of Imfinzi in non-small cell lung cancer 
EPM Magazine
?This is the first treatment approved for stage III unresectable non-small cell lung cancer to reduce the risk of the cancer progressing, when the cancer has not worsened after chemoradiation,? stated Dr Richard Pazdur, director of the FDA's Oncology ...
US clears AZ' Imfinzi for lung cancer PharmaTimes
FDA Approves Imfinizi to Reduce NSCLC Progression Specialty Pharmacy Times
US FDA approves Imfinzi for unresectable Stage III non-small cell lung cancer The FINANCIAL
Managed Care magazine  -Financial Times 
all 31 news articles » 


Making milestones against non-small cell lung cancer - Yale News



Yale News
 
Making milestones against non-small cell lung cancer 
Yale News
?Liquid biopsies are not quite as sensitive as a tumor biopsy, but some evidence suggests that they might actually give a more realistic view of the disease throughout the entire body.? Clinical research in NSCLC is being accelerated by innovative ...

and more » 


Non-Small Cell Lung Cancer Research Report 2018 - Global API Manufacturers, Marketed and Phase III Drugs ... - Business Wire (press release)



Non-Small Cell Lung Cancer Research Report 2018 - Global API Manufacturers, Marketed and Phase III Drugs ... 
Business Wire (press release)
Non-Small Cell Lung Cancer - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018' report provides comprehensive insights about marketed and Phase III products for Non-Small Cell Lung Cancer . The report includes information of ...

and more » 


Avelumab Falls Short in Phase III NSCLC Trial - OncLive



PMLiVE
 
Avelumab Falls Short in Phase III NSCLC Trial 
OncLive
Avelumab (Bavencio) missed the primary endpoint of improving overall survival (OS) in pretreated patients with non?small cell lung cancer (NSCLC), according to findings from the phase III JAVELIN Lung 200 Trial.1. According to Merck KGaA and Pfizer ...
Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on Phase III JAVELIN Lung 200 Trial of Avelumab ... PR Newswire (press release)
Bavencio Fails to Improve Survival in Lung Cancer Trial P&T Community
Pfizer, Merck KGaA lung cancer drug fails BioPharma Dive
MarketWatch  -MedPage Today  -PMLiVE 
all 27 news articles » 


Immunotherapy Drug OK'd for Lung Cancer - Newsmax



Newsmax
 
Immunotherapy Drug OK'd for Lung Cancer 
Newsmax
AstraZeneca's immunotherapy drug Imfinzi has won crucial approval from U.S. regulators for use in lung cancer, opening up a multibillion-dollar market for a medicine that has so far lagged behind competitors. The U.S. Food and Drug Administration (FDA ...
Pharmalittle: Biogen argues investors overreacted; AstraZeneca wins a key immunotherapy approval STAT
US FDA Approves AstraZeneca's Immunotherapy for Lung Cancer Journal of Clinical Pathways

all 5 news articles » 


Small-cell Lung Cancer: A Phase 2 Study of p53 Vaccination With Checkpoint Inhibition - Cancer Therapy Advisor



Cancer Therapy Advisor
 
Small-cell Lung Cancer: A Phase 2 Study of p53 Vaccination With Checkpoint Inhibition 
Cancer Therapy Advisor
Researchers are evaluating whether adding a dendritic cell?based p53 vaccine to combination checkpoint inhibition will improve outcomes among patients with recurrent SCLC. Title: Combination Immunotherapy With Ipilimumab and Nivolumab Plus a Dendritic ...

 


Not All Small-Cell Lung Cancer Treatment Is Equal - Cure Today - Curetoday.com



Not All Small-Cell Lung Cancer Treatment Is Equal - Cure Today 
Curetoday.com
A new study showed that a large percentage of patients do not receive standard-of-care.

and more »